{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:33:47Z","timestamp":1775921627170,"version":"3.50.1"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,3,8]]},"DOI":"10.18632\/oncotarget.26735","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T14:21:31Z","timestamp":1552054891000},"page":"1932-1942","source":"Crossref","is-referenced-by-count":6,"title":["Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia"],"prefix":"10.18632","volume":"10","author":[{"given":"Stacey J.","family":"Baker","sequence":"first","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C.","family":"Cosenza","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.V.","family":"Ramana Reddy","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Premkumar Reddy","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2019,3,8]]},"reference":[{"key":"1","first-page":"8","article-title":"Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras","author":"Shannon","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","article-title":"Targeting oncogenic Ras signaling in hematologic malignancies","volume":"120","author":"Shannon","year":"2012","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pcl.2014.09.003","article-title":"Juvenile myelomonocytic leukemia","volume":"62","author":"Dvorak","year":"2015","journal-title":"Pediatr Clin North Am"},{"key":"4","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Vivent","year":"2015","journal-title":"Nat Genet"},{"key":"5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/11631360-000000000-00000","article-title":"Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations","volume":"14","author":"Kojima","year":"2012","journal-title":"Paediatr Drugs"},{"key":"6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cell.2016.03.045","article-title":"A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling","volume":"165","author":"Guha","year":"2016","journal-title":"Cell"},{"key":"7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41408-017-0018-7","article-title":"Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care","volume":"7","author":"Silverman","year":"2017","journal-title":"Blood Cancer J"},{"key":"8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2017.11.006","article-title":"A phase 1\/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia","volume":"64","author":"Silverman","year":"2018","journal-title":"Leuk Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood-2018-99-119259","article-title":"Phase 2 expansion study of oral rigosertib combined with azacytidine (AZA) in patients (Pts) with higher-risk (HR) myelodysplastic syndromes (MDS): efficacy and safety results in HMA treatment na\u00efve & relapsed (Rel)\/refaractory (Ref) patients","volume":"132","author":"Ohanian","year":"2018","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.1038\/srep07310","article-title":"Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome","volume":"4","author":"Guo","year":"2014","journal-title":"Sci Rep"},{"key":"11","first-page":"4235","article-title":"Effects of rigosertib (RIGO) alone or in combination with azacytidine or vorinostat on epigenetic reprogramming of CD34+ cells in the myelodysplastic syndrome","volume":"130","author":"Reddy","year":"2017","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Kreuzer","year":"2016","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1182\/blood.V118.21.3808.3808","article-title":"A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib)","volume":"118","author":"Felsher","year":"2011","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1073\/pnas.0307203101","article-title":"Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder","volume":"101","author":"Shannon","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1172\/JCI20476","article-title":"Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease","volume":"113","author":"Gilliland","year":"2004","journal-title":"J Clin Invest"},{"key":"16","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood-2006-09-047530","article-title":"K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem\/progenitor cells","volume":"109","author":"Braun","year":"2007","journal-title":"Blood"},{"key":"17","first-page":"e59","article-title":"Oncogenic Kras initiates leukemia in hematopoietic stem cells","volume":"7","author":"Braun","year":"2009","journal-title":"PLoS Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood-2008-01-134262","article-title":"Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation","volume":"113","author":"Fleming","year":"2009","journal-title":"Blood"},{"key":"19","first-page":"76ra27","article-title":"A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice","volume":"3","author":"Braun","year":"2011","journal-title":"Sci Transl Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/leu.2016.14","article-title":"Targeting the PI3K\/Akt pathway in murine MDS\/MPN driven by hyperactive Ras","volume":"30","author":"Braun","year":"2016","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Der","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bcp.2018.10.022","article-title":"RASpecting the oncogene: New pathways to therapeutic advances","volume":"158","author":"Campbell","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nature12830","article-title":"Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness","volume":"504","author":"Morrison","year":"2013","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2015.136002","article-title":"Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency","volume":"101","author":"Morgan","year":"2016","journal-title":"Haematologica"},{"key":"25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates","volume":"14","author":"Loh","year":"2008","journal-title":"Cancer Cell"},{"key":"26","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1182\/blood-2010-04-281527","article-title":"Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic\/monocytic precursors in a murine model of chronic myelomonocytic leukemia","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1172\/JCI69927","article-title":"Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110\u03b1","volume":"124","author":"Zhao","year":"2014","journal-title":"J Clin Invest"},{"key":"28","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1182\/blood-2012-12-475863","article-title":"Nras(G12D\/+)promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Li","year":"2014","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Harvey","year":"2012","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Barbui","year":"2012","journal-title":"N Engl J Med"},{"key":"32","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1073\/pnas.1315464111","article-title":"B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development","volume":"111","author":"Reddy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T09:57:26Z","timestamp":1694685446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.26735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,8]]},"references-count":32,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,3,8]]}},"alternative-id":["26735","30956775"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.26735","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,8]]}}}